Combination of Bortezomib, Fludarabine and Cyclophosphamide
Vel-FC-4003
Phase 2 small_molecule active
Quick answer
Combination of Bortezomib, Fludarabine and Cyclophosphamide for Mantle Cell Lymphoma Recurrent is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Mantle Cell Lymphoma Recurrent
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active